Secondary outcomes include TRAEs, immune-related best overall response (irBOR), immune-related PFS (irPFS), PFS, OS, DOR, PD-L1 tumor expression, serum cytokines, and number of patients with anti-avelumab antibodies. Here, CD274 is linked to neoplasm.